[1] |
Hu D, Hu D, Liu L, et al. Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease[J]. EBioMedicine, 2020, 54: 102723.
|
[2] |
Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis[J]. Hum Mol Genet, 2001, 10(11): 1215-1220.
doi: 10.1093/hmg/10.11.1215
pmid: 11371514
|
[3] |
Porto AG, Brun F, Severini GM, et al. Clinical spectrum of PRKAG2 syndrome[J]. Circ Arrhythm Electrophysiol, 2016, 9(1): e003121.
|
[4] |
Arad M, Benson DW, Perez-Atayde AR, et al. Con-stitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy[J]. J Clin Invest, 2002, 109(3): 357-362.
|
[5] |
Burwinkel B, Scott JW, Bührer C, et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency[J]. Am J Hum Genet, 2005, 76(6): 1034-1049.
doi: 10.1086/430840
pmid: 15877279
|
[6] |
Torok RD, Austin SL, Phornphutkul C, et al. PRKAG2 mutations presenting in infancy[J]. J Inherit Metab Dis, 2017, 40(6): 823-830.
|
[7] |
Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy[J]. Circulation, 2001, 104(25): 3030-3033.
doi: 10.1161/hc5001.102111
pmid: 11748095
|
[8] |
Akman HO, Sampayo JN, Ross FA, et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase[J]. Pediatr Res, 2007, 62(4): 499-504.
doi: 10.1203/PDR.0b013e3181462b86
pmid: 17667862
|
[9] |
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2020, 142(25): e558-e631.
|
[10] |
Murphy RT, Mogensen J, Mcgarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history[J]. J Am Coll Cardiol, 2005, 45(6): 922-930.
doi: 10.1016/j.jacc.2004.11.053
pmid: 15766830
|
[11] |
Laforêt P, Richard P, Said MA, et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis[J]. Neuromuscul Disord, 2006, 16(3): 178-182.
|
[12] |
Thevenon J, Laurent G, Ader F, et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations[J]. Europace, 2017, 19(4): 651-659.
doi: 10.1093/europace/euw067
pmid: 28431061
|
[13] |
Lopez-Sainz A, Dominguez F, Lopes LR, et al. Clinical features and natural history of PRKAG2 variant cardiac glycogenosis[J]. J Am Coll Cardiol, 2020, 76(2):186-197.
doi: S0735-1097(20)35324-9
pmid: 32646569
|
[14] |
Gollob MH, Green MS, Tang AS, et al. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy[J]. Curr Opin Cardiol, 2002, 17(3): 229-234.
doi: 10.1097/00001573-200205000-00004
pmid: 12015471
|
[15] |
Yavari A, Sarma D, Sternick EB. Human γ2-AMPK Mutations[J]. Methods Mol Biol, 2018, 1732: 581-619.
doi: 10.1007/978-1-4939-7598-3_37
pmid: 29480501
|